Opinion

Video

EHA 2024: Teclistimab in High-Risk Relapsed/Refractory Multiple Myeloma

Author(s):

Joseph Mikhael, MD

Dr. Mikhael discusses the safety and usefulness of tesclistimab in patients with high-risk refractory multiple myeloma.

Video content above is prompted by the following question:

  1. Discuss the data presented at EHA 2024 on the efficacy and safety of teclistimab in patients with relapsed/refractory multiple myeloma (RRMM) with high-risk features: a subgroup analysis of the phase 1/2 MajesTEC-1 study. (Abstract)
    1. What was the objective of the subgroup analysis of this study?
    2. How was this study designed/what methodology was used?
    3. What results were presented?
      1. N=165
    4. N=24 aged ≥75 years
    5. N=20 ISS stage III
    6. N=38 high-risk cytogenetics
    7. N=28 extramedullary disease
    8. N=18 bone marrow plasma cells
    9. N=50 penta-drug refractory
      1. Median follow up ~30 months across subgroups
      2. Objective Response Rate (ORR)
      3. Median duration of response (mDOR)
      4. Safety
Related Videos
Leland Metheny, MD, University Hospitals Seidman Cancer Center
Jason Porter, MD, an expert on lung cancer
1 KOL is featured in this program.
1 KOL is featured in this program.
Joseph Mikhael, MD, an expert on multiple myeloma
Jason Porter, MD, an expert on lung cancer
Jason Porter, MD, an expert on lung cancer
Joseph Mikhael, MD, an expert on multiple myeloma
Alfred L. Garfall, MD, an expert on multiple myeloma
Alfred L. Garfall, MD, an expert on multiple myeloma
Related Content
Leland Metheny, MD, University Hospitals Seidman Cancer Center
August 30th 2024

Triple-Target CAR T Cells: Benefits and Challenges

Maggie L. Shaw
In part 1 of our interview with Leland Metheny, MD, he explained how a new triple-target chimeric antigen receptor (CAR) T-cell therapy works in multiple myeloma.
Regeneron logo | Image credit: Casimiro – stock.adobe.com
August 21st 2024

FDA Issues CRL for Linvoseltamab in R/R Multiple Myeloma

Hayden E. Klein
The complete response letter (CRL) was issued based on a pre-approval inspection at a third-party fill/finish manufacturer.
stem cells | Image Credit: jarun011-stock.adobe.com
August 20th 2024

Second ASCT Extends Survival in Relapsed Multiple Myeloma

Maggie L. Shaw
To continue the response they experienced with a first autologous stem‐cell transplant (ASCT) for their multiple myeloma, patients in this analysis received a second ASCT, with French investigators evaluating their outcomes.
MM treatment | Image Credit: Dzmitry-stock.adobe.com
August 14th 2024

Challenges With Pomalidomide for Patients With Comorbid RRMM, CKD

Maggie L. Shaw
Patients who have comorbid relapsed/refractory multiple myeloma (RRMM) and advanced chronic kidney disease (CKD) are often excluded from clinical trials, leaving treatment gaps for these high-risk patients.
MM blood test | Image Credit: luchschenF-stock.adobe.com
August 6th 2024

Novel Therapies Needed for Older Patients With RRMM

Maggie L. Shaw
Relapsed/refractory multiple myeloma (RRMM) remains an incurable hematologic cancer, often resulting in patients treated with several classes of medications—particularly older patients.
FDA | Image Credit: ra2studio-stock.adobe.com
July 31st 2024

Daratumumab and Hyaluronidase-fihj–Based Quadruplet Regimen Approved in MM

Maggie L. Shaw
Daratumumab/hyaluronidase-fihj plus bortezomib, lenalidomide, and dexamethasone is now approved by the FDA to treat newly diagnosed multiple myeloma (MM) in patients eligible for autologous stem cell transplant.

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2024 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
CH LogoCenter for Biosimilars Logo